PRESS RELEASE
ENS High Scientific Council Position Paper
Unlocking the Potential of Radiopharmaceuticals in Europe
Part 2: Strategic Challenges and Policy Priorities
Brussels, 15th April 2026 — The European Nuclear Society High Scientific Council (HSC) has published a new Position Paper titled “Unlocking the Potential of Radiopharmaceuticals in Europe – Part 2: Strategic Challenges and Policy Priorities”. The paper provides a structured analysis of the key obstacles facing the radiopharmaceutical sector in Europe and sets out concrete policy recommendations to address them.
Radiopharmaceuticals are transforming healthcare by enabling precise diagnosis and targeted, personalised therapies for millions of patients across Europe. Yet, despite their growing importance, the full potential of nuclear medicine remains constrained by structural, regulatory, and supply chain challenges.
In this context, and building on the latest introductory HSC Briefing Paper, this Position Paper moves from scene-setting to action by identifying critical challenges across five key areas: supply chain vulnerabilities, technical manufacturing constraints, radiation safety frameworks, regulatory complexity, and the need for sustained investment in infrastructure and human capital.
These challenges reflect not only the highly time-sensitive nature of radiopharmaceuticals but also the complexity of their production and delivery.
In response, the ENS High Scientific Council formulates a set of targeted recommendations aimed at strengthening the radiopharmaceutical ecosystem in Europe, focusing on resilience, innovation, regulatory efficiency, and long-term sustainability, with the overarching goal of ensuring equitable patient access.
The ENS High Scientific Council emphasises that these challenges extend beyond scientific and industrial considerations, carrying important strategic implications for Europe’s sovereignty, innovation capacity, and long-term healthcare resilience.
The ENS High Scientific Council is composed of scientists of high repute from several European countries and serves as an independent advisory body to the European Nuclear Society on nuclear science and technology and their impact on society.
The European Nuclear Society invite you to download and read the full ENS HSC Position Paper,
and explore its recommendations for building a secure and sustainable radiopharmaceutical ecosystem in Europe.
For press inquiries, interview requests, or more information, please contact the ENS Communications and Project Manager, Mattia Baldoni,
mattia.baldoni@euronuclear.org
To further explore these findings, the ENS will host a webinar on Wednesday, 29 April at 1:00 PM, featuring the HSC member Sarah Baatout (Deputy Institute Director of Nuclear Medical Applications at SCK CEN and ENS High Scientific Council Member), which will present the key conclusions of the paper and discuss the actions needed to secure a resilient, innovative, and patient-centred radiopharmaceutical landscape in Europe.
